SPOTLIGHT: Medicaid spends big bucks on antipsychotics for elderly

Medicaid spends more money on antipsychotics than on any other class of drugs. That's partly because nursing homes depend on these drugs to quiet patients with dementia, a use that isn't approved by the FDA--in fact, is warned against because of the risk of severe side effects. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.